Funding for the four UK Diagnostic Evidence Co-operatives (DECs), which were set up by the National Institute for Health Research (NIHR) in 2013, is coming to an end at the close next year. That means a restructuring of the activities and new methods of funding are imminent.
UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure
Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.
More from United Kingdom
• By
The UK’s “New Approach” to regulation has created a lot of noise, but what’s the end product? asks Taylor Wessing partner Alison Dennis, who says the UK medtech regulator should look afresh at the EU’s ready-made solution.
• By
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
Medtech Insight sat down with Anja Streicher, chief marketing officer at Women of Wearables, a global community offering events and education resources to support the femtech industry, to discuss trends in the women's wearables tech market, challenges and innovators pushing the boundaries.
More from Europe
• By
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
• By
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.